148 related articles for article (PubMed ID: 21783418)
1. Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Mitsudomi T
Lancet Oncol; 2011 Aug; 12(8):710-1. PubMed ID: 21783418
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of gefitinib and erlotinib.
Levêque D
Lancet Oncol; 2011 Nov; 12(12):1093. PubMed ID: 22041538
[No Abstract] [Full Text] [Related]
3. Optimising therapy for EGFR-addicted NSCLC: just the start.
Govindan R; Subramanian J
Lancet Oncol; 2012 Mar; 13(3):216-7. PubMed ID: 22285167
[No Abstract] [Full Text] [Related]
4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
5. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Lee VW; Schwander B; Lee VH
Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
8. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
9. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Giuliani J; Martelli S; Remo A; Bonetti A
Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR in non-small-cell lung cancer.
Doroshow JH
N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
[No Abstract] [Full Text] [Related]
12. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
13. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
15. [Erlotinib in non-small cell lung cancer].
Takeda M; Okamoto I
Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
[TBL] [Abstract][Full Text] [Related]
16. Assessing EGFR mutations.
Marchetti A; Felicioni L; Buttitta F
N Engl J Med; 2006 Feb; 354(5):526-8; author reply 526-8. PubMed ID: 16452569
[No Abstract] [Full Text] [Related]
17. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Yoshimura N; Okishio K; Mitsuoka S; Kimura T; Kawaguchi T; Kobayashi M; Hirashima T; Daga H; Takeda K; Hirata K; Kudoh S
J Thorac Oncol; 2013 Jan; 8(1):96-101. PubMed ID: 23207920
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
[TBL] [Abstract][Full Text] [Related]
19. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
